Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports. Check Now!
Dec 22, 2016
The only word that described 2016’s pharma M&A market was “slow.” Some do predict that new year—and administration—could revive energy in the deal making arena, the changes might not happen that fast. The reasons are aplenty, as shares have been sagging under the weight of investor fears of drug-pricing reform. ...
Read More...
Roche’s HER2-Positive Breast Cancer Treatment Franchise
Aug 13, 2024
Transforming Multiple Myeloma Treatment: The Promise of Novel Drug Classes
Jul 24, 2024
-Agonist.png "Toll-like Receptors Agonist")
Newsletter/Whitepaper